Harte Hanks (HHS) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
15 May, 2026Executive summary
Revenue for Q1 2026 was $37.3 million, down 10.3% year-over-year, with declines across all segments.
Operating loss increased to $0.8 million from $0.04 million in Q1 2025, driven by lower revenues and reduced restructuring charges.
Net loss widened to $0.6 million, or $0.08 per share, compared to $0.4 million, or $0.05 per share, in the prior year.
Advanced sector-aligned growth strategy, focusing on higher-value services and technology-enabled delivery.
Maintained a strong balance sheet with no outstanding debt and $4.5 million in cash at quarter-end.
Financial highlights
Revenue decreased by $4.3 million year-over-year, primarily due to a $3.3 million drop in Fulfillment & Logistics Services.
EBITDA for Q1 2026 was $0.3 million, down from $1.0 million in Q1 2025; Adjusted EBITDA was $0.7 million, down from $1.8 million.
Operating expenses fell 8.6% to $38.0 million, mainly from lower production/distribution and restructuring costs.
Cash and cash equivalents were $4.5 million at March 31, 2026, with $24.3 million available under the credit facility.
No outstanding debt as of March 31, 2026.
Outlook and guidance
Management believes liquidity is sufficient for the next twelve months, with no substantial doubt about going concern.
Positioned to deliver positive EBITDA throughout 2026, leveraging a strong balance sheet and sector focus.
No dividends were paid or planned; share repurchase authorization of $4.1 million remains available.
Latest events from Harte Hanks
- Operational improvements, governance enhancements, and key votes position the company for growth.HHS
Proxy filing9 Apr 2026 - Positive EBITDA and improved net results in FY 2025 despite lower revenue and segment declines.HHS
Q4 202518 Mar 2026 - Q2 net loss of $27.8M from pension charge; Sales Services surged, cash strong, no debt.HHS
Q2 20242 Feb 2026 - Q3 revenue up 1.1% YoY; profit metrics declined; Q4 revenue expected to contract.HHS
Q3 202414 Jan 2026 - Shareholders to vote on board, executive pay, and auditor as company targets growth and innovation.HHS
Proxy Filing2 Dec 2025 - Beneficial ownership update adds Rosenbachs as 26.26% holders for 2025 meeting.HHS
Proxy Filing2 Dec 2025 - Q3 2025 revenue dropped 17% with net loss, but cost controls and new deals support outlook.HHS
Q3 202512 Nov 2025 - Revenue dropped 14.2% but net loss narrowed and EBITDA stayed positive in Q2 2025.HHS
Q2 20258 Aug 2025 - Revenue fell 8.6% to $41.6M, net loss widened, but liquidity and new business remain strong.HHS
Q1 20256 Jun 2025